You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
CTDetailNew
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointment
Find a Condition or Treatment
Find a Doctor
Menu
MAIN
Back to Home
About Us
Corporate Profile
Newsroom
Visitors Information
Contact Us
Patient Care
Specialties & Services
Your Clinic Visit
Cancer Information & Patient Support
E-Services
Find a Doctor
Research & Innovation
Research Labs
Programmes
Facilities
Our Researchers
Clinical Trials
SingHealth Research
Education & Training
Overview
Division of Cancer Education
Events
SingHealth Academy
Careers
Sponsorship
Scholarships
Giving
Why Give
Get Involved
Your Gift at Work
Be Informed
Make a Gift
Our Campaign
Volunteer
Specialties & Services
Back to Home
Goh Cheng Liang Proton Therapy Centre
Haematology
Medical Oncology
Surgery & Surgical Oncology, SGH and NCCS
Radiation Oncology
Oncologic Imaging
Supportive & Palliative Care
Comprehensive Liver Cancer Clinic
Cancer Genetics Service
Lung Multidisciplinary Clinic
Nursing
NCCS Oncology @ SKH
NCCS Oncology Clinic @ CGH
Department of Psychosocial Oncology
Cancer Education and Information
Your Clinic Visit
Back to Home
Book an Appointment
When seeing a doctor
Pharmacy
Outpatient Pharmacy
Oncology Pharmacy
Search a medication
FAQ
Medicine
Charges & Payment
Financial Aid
Video Consultation
Rights & Responsibilities as a Patient
Cancer Information & Patient Support
Back to Home
For Patients
For Caregivers
Publications
Cancer Information Booklets
In Good Health
Inspirational Patient & Caregiver Awards
Patient Stories
E-Services
Back to Home
Make/Change/Cancel Appointment
Request for Medical Report
Health Buddy App
Find a Doctor
Home
to skip to the main content on a page
to skip to the main content on a page
About Us
Back to Home
Corporate Profile
Vision & Mission
NCCS Leadership
Annual Report
Awards
Key Milestones
Whistle-blowing Policy
Newsroom
Press Releases
Check Fake News
Visitors Information
Contact Us
Feedback Form
Patient Liaison Service
Patient Care
Back to Home
Specialties & Services
Goh Cheng Liang Proton Therapy Centre
Haematology
Medical Oncology
Surgery & Surgical Oncology, SGH and NCCS
Radiation Oncology
Oncologic Imaging
Supportive & Palliative Care
Comprehensive Liver Cancer Clinic
Cancer Genetics Service
Lung Multidisciplinary Clinic
Nursing
NCCS Oncology @ SKH
NCCS Oncology Clinic @ CGH
Department of Psychosocial Oncology
Cancer Education and Information
Your Clinic Visit
Book an Appointment
When seeing a doctor
Pharmacy
Medicine
Charges & Payment
Financial Aid
Video Consultation
Rights & Responsibilities as a Patient
Cancer Information & Patient Support
For Patients
For Caregivers
Publications
Patient Stories
E-Services
Make/Change/Cancel Appointment
Request for Medical Report
Health Buddy App
Find a Doctor
Research & Innovation
Back to Home
Research Labs
Cellular & Molecular Research
Medical Sciences
Clinical Trials & Epidemiological Sciences
NCCS Research Committee & Scientific Advisory Board
Research Divisions Organisation Chart
Programmes
Disease Focus
Research Themes
Joint Breast Cancer Registry
Asia-Pacific Hepatocellular Carcinoma Trials Group
The VICTORY Consortium
ANCHOR
Facilities
Overview
Specialised Units
Shared Facilities
Shared Services
Research Contracts and Commercialisation
Our Researchers
Division of Medical Oncology
Division of Surgery & Surgical Oncology, SGH and NCCS
Division of Radiation Oncology
Division of Oncologic Imaging
Division of Supportive and Palliative Care
Cellular and Molecular Research
Division of Medical Sciences
Clinical Trials & Epidemiological Sciences
Research Biennial Book
Clinical Trials
About Clinical Trials
Current Clinical Trials
ECRU
About Clinical Trials & Epidemiological Sciences
Clinical Trials Office
Biostatistics and Epidemiology Unit
SingHealth Research
Education & Training
Back to Home
Overview
Division of Cancer Education
Undergraduate Education Unit
Postgraduate Education Unit
Nursing Education Unit
Faculty Development & Support Education Unit
Primary Care Oncology Education Unit
Communications, Mentoring, Ethics and Professionalism Education Unit
Medical Humanities Education Unit
Events
SingHealth Academy
Careers
Back to Home
Sponsorship
Career Conversion Programme
Scholarships
Giving
Back to Home
Why Give
About Us
Funding Innovative Research
Preventing Cancer
Advancing Medical Education
Helping Our Patients
Furthering Donor Impact
How Your Gift Helps
Get Involved
Honouring Your Gift
Become a Corporate Donor
Leave Your Legacy
Fundraise for Us
Join a Special Event
Your Gift at Work
Stories of Hope
Researchers in Action
Support for Patients
Our Work in the Community
Training Future Experts
Be Informed
Our Publications
Financial Statements
Make a Gift
Our Campaign
Make More Survivors
Jeans For Genes
Women VS Cancer
BCAM 2024
LCAM 2023
Volunteer
Home
>
Patient Care
>
Conditions and Treatment
>
Lutetium-177 PSMA (LuPSMA) radionuclide therapy
Facebook
WhatsApp
Email Us
share
Font Resize
A-
A
A+
Print
Lutetium-177 PSMA (LuPSMA) radionuclide therapy
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - What it is
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Symptoms
Lutetium-177 PSMA radionuclide therapy is used for treating patients with advanced prostate cancer. Prostate cancers, in particular those that have spread to other sites of the body or become resistant to hormonal therapies, express a unique substance on their cell surface called prostate specific membrane antigen (PSMA). LuPSMA radionuclide therapy involves using a radioactive molecule (Lutetium-177) and PSMA substance that specifically attaches to cells with high PSMA expression. This radioactive molecule is taken up into prostate cancer cells, or wherever the disease has spread and enables delivery of high doses of targeted radiation to sites of prostate cancer whilst sparing most normal tissues. This is called radionuclide therapy as it uses radiation to kill prostate cancer cells.
Why do I need this treatment?
The use of LuPSMA therapy is largely for patients who have progressive metastatic hormone-resistant prostate cancer. You may be referred for this treatment if there is progression of your condition despite having undergone conventional therapy (such as hormonal treatment and chemotherapy). Hormonal treatment and other systemic therapies may control the disease for some periods of time, however many patients eventually suffer a relapse of the disease.
The benefits of this targeted radionuclide therapy may include shrinkage of tumours, a reduction in blood Prostate Specific Antigen (PSA) level, improvement in symptoms such as pain and a general improvement in well-being.
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - How to prevent?
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Causes and Risk Factors
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Diagnosis
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Treatments
What does it involve?
LuPSMA treatment is an outpatient treatment. It will be administered via an intravenous line into the veins of your arms.
You will receive up to 4 -6 cycles of LuPSMA treatment at 6-8 week intervals.
What precautions must I take for the treatment?
Standard supportive drugs, hormonal therapy, biosphosphonate therapy or palliative radiotherapy while on LuPSMA therapy is permissible as clinically indicated. Concurrent chemotherapy while receiving LuPSMA therapy is currently not permitted.
It is important to tell your doctor about any treatments or medications you may be taking, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments, and any changes to these medications during your LuPSMA therapy.
What are the risks of the treatment?
Possible short term side effects (within weeks to months of treatment):
1. Nausea (very common: more than 1 in 10)
This is usually mild and, if needed, can be treated with anti-nausea medication.
2. Injury to salivary or lacrimal (tear) glands (very common: more than 1 in 10)
These gland cells have PSMA-receptors, which LuPSMA will attach to. Therefore, the glands will receive radiation. This may result in inflammation (swelling) of the glands which may lead to pain or decreased production of saliva and/or tears. This will most likely be temporary and resolve with time. Permanent injury (e.g. reduced production of saliva or tears) is possible but is usually mild and can be alleviated with artificial saliva and tear drops.
3. Increased pain or pressure effects from swelling due to radiation damage at sites of tumours (common: between 1 in 10 and 1 in 100)
This is usually temporary but may require increase in painkiller requirements.
4. Flu-like symptoms (common: between 1 in 10 and 1 in 100)
As tumours die, this can result in flu-like symptoms including low grade fevers and fatigue.
5. Bleeding or infection as a result of reduction in blood count (uncommon: likelihood of less than 1 in 100 to 1 in 1000)
The extent of blood count reduction may be influenced by prior therapies (e.g. chemotherapy). If you have very extensive bone metastases, this may also increase the likelihood of reduced blood count. Mild reduction in blood count that can be measured through blood tests without any resulting symptoms may be more common (between 1 in 10 and 1 in 100).
6. Kidney failure (uncommon: likelihood of less than 1 in 100 to 1 in 1000)
Reduced glomerular filtration rate of the kidneys has been observed following LuPSMA therapy, however this usually does not result in kidney dysfunction clinically for most patients.
Possible longer-term side effects
Longer-term side effects may include risk of developing secondary malignancies. The precise increase in risk is not known but thought to be very small (less than 1 in 100) and will depend somewhat on the radiation doses absorbed during the treatment. However, the risk of serious sequelae is relatively rare and typically involves blood disorders that may develop several years after treatment.
What can I expect after the treatment?
After each treatment, a whole body 2-dimensional scan and a more detailed 3-dimensional scan will be performed to see where the radiation has gone to. This scan will take approximately 45-60 minutes to complete. Most patients will feel well and be allowed to go home on the day of treatment.
However, you will be mildly radioactive for a few days and there may be some restrictions on close personal contact including with pregnant women or children.
Your blood will be taken and tested (full blood count, urea and electrolytes, liver function tests, PSA) at 14 and 28 days after the treatment.
Further LuPSMA treatments can be considered for patients who responded to initial cycles of LuPSMA but subsequently progressed, provided they continued to meet the eligibility criteria for treatment.
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Preparing for surgery
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Post-surgery care
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Other Information
Symptoms
Article contributed by
Nuclear Medicine and Molecular Imaging
,
Singapore General Hospital
The information provided is not intended as medical advice.
Terms of use
. Information provided by
Our Breast Team
Filter:
By designation or sub-specialty
By Designation:
By Sub-Specialty:
TOP
[]
Related Conditions
Related Medicine
Healthy Living Tips
by
View more
Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.
Braces How to Take Care
Festive Feasting How to Avoid Overeating
Post-Stroke Exercises (Lower Limb Strength Training)
Post-Stroke Exercises (Upper Limb Strength Training)
×
SUBSCRIBE VIA EMAIL
Subscribe to our mailing list to get the updates to your email inbox...
Find a Doctor
Condition & Treatment
Home
Appointment
E-services